However, there is no published data comparing treatment by
neoadjuvant chemotherapy or hypofractionation with standard concomitant chemoradiation.
Neoadjuvant treatment is given before surgery with the goal of shrinking tumors and helping to improve surgical outcomes.
The sensitivity and specificity of conventional MRI sequences is well known to be limited in the detection of response to
neoadjuvant treatment.
Our faculty supports the administration of
neoadjuvant treatment with chemoradiation for Stage 2 patients carrying risk factors for lymph node metastasis and all patients with Stage 3 esophagogastric cancers.
The aim of this study was to compare the efficacy of MRI and US, which are commonly used in the pre-surgery determination of tumor size and the follow-up of breast cancer patients treated with
neoadjuvant chemotherapy and to guide clinicians on the appropriate treatment plan.
Keywords: Advanced adenocarcinoma rectal cancer, Chemo-radiation, Complete clinical response (cCR),
Neoadjuvant chemoradiotherapy, Pelvic CT/MRI.
The use of MRI for the local staging of rectal tumors has greatly helped in identifying patients at a risk of incomplete tumor excision and in selecting them for
neoadjuvant treatment [5].
Groth, M.D., from the Baylor College of Medicine in Houston, and colleagues conducted a retrospective study of patients aged 18 to 80 years in the National Cancer Database with clinically staged, locally advanced esophageal adenocarcinoma who underwent a margin-negative esophagectomy following
neoadjuvant chemotherapy or chemoradiation.
Although these results suggest that ERAS programs are safe and effective when applied to gastrectomy, we found that most studies investigating ERAS programs for gastric cancer excluded patients who were administered preoperative
neoadjuvant chemotherapy.[12],[13],[14]
Also trending in medical dermatology are best practices for intralesional injections of 5-FU to treat the often challenging isomorphic squamous cell carcinomas (SCCs) or keratoacanthomas on the lower leg, as well as use of
neoadjuvant hedgehog inhibitors to shrink large skin cancer lesions, according to Glenn David Goldman, MD.
Neoadjuvant chemotherapy, given for five to six months before surgery, is the standard treatment for some women with newly diagnosed invasive, but operable, breast cancer.